BROOMFIELD, Colo.--(BUSINESS WIRE)--Biodesix Inc, a fully integrated molecular diagnostic company dedicated to personalizing medicine, announced today the publication of “Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs,” by Lazzari, et al. in the November issue of the Journal of Thoracic Oncology, currently available online.
